Company profile GALT
After 38 days of this quarter the interest is at 68.0. Based on that we can calculate that during remaining 53 days it will total up to 163.0. Galectin Therapeutics expected interest is significantly higher compared to previous quarter (+482.1%) and same quarter last year (+262.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 55 | 81 47.3% QoQ | 64 -21.0% QoQ | 76 18.8% QoQ |
| 2020 | 65 18.2% YoY -14.5% QoQ | 121 49.4% YoY 86.2% QoQ | 88 37.5% YoY -27.3% QoQ | 19 -75.0% YoY -78.4% QoQ |
| 2021 | 65 0.0% YoY 242.1% QoQ | 87 -28.1% YoY 33.8% QoQ | 201 128.4% YoY 131.0% QoQ | 64 236.8% YoY -68.2% QoQ |
| 2022 | 86 32.3% YoY 34.4% QoQ | 105 20.7% YoY 22.1% QoQ | 39 -80.6% YoY -62.9% QoQ | 57 -10.9% YoY 46.2% QoQ |
| 2023 | 45 -47.7% YoY -21.1% QoQ | 42 -60.0% YoY -6.7% QoQ | 49 25.6% YoY 16.7% QoQ | 28 -50.9% YoY -42.9% QoQ |
| 2024 | 68 51.1% YoY 142.9% QoQ | - | - | - |
The average 5 years interest of Galectin Therapeutics was 5.77 per week. The last year interest of Galectin Therapeutics compared to the last 5 years has changed by -29.98%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -23.92%.
After 38 days of this quarter the interest is at 68.0. Based on that we can calculate that during remaining 53 days it will total up to 163.0. Galectin Therapeutics expected interest is significantly higher compared to previous quarter (+482.1%) and same quarter last year (+262.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 55 | 81 47.3% QoQ | 64 -21.0% QoQ | 76 18.8% QoQ |
| 2020 | 65 18.2% YoY -14.5% QoQ | 121 49.4% YoY 86.2% QoQ | 88 37.5% YoY -27.3% QoQ | 19 -75.0% YoY -78.4% QoQ |
| 2021 | 65 0.0% YoY 242.1% QoQ | 87 -28.1% YoY 33.8% QoQ | 201 128.4% YoY 131.0% QoQ | 64 236.8% YoY -68.2% QoQ |
| 2022 | 86 32.3% YoY 34.4% QoQ | 105 20.7% YoY 22.1% QoQ | 39 -80.6% YoY -62.9% QoQ | 57 -10.9% YoY 46.2% QoQ |
| 2023 | 45 -47.7% YoY -21.1% QoQ | 42 -60.0% YoY -6.7% QoQ | 49 25.6% YoY 16.7% QoQ | 28 -50.9% YoY -42.9% QoQ |
| 2024 | 68 51.1% YoY 142.9% QoQ | - | - | - |
The average 5 years interest of Galectin Therapeutics was 5.77 per week. The last year interest of Galectin Therapeutics compared to the last 5 years has changed by -29.98%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -23.92%.
After 38 days of this quarter the interest is at 63.0. Based on that we can calculate that during remaining 53 days it will total up to 151.0. Galectin Therapeutics news expected interest is significantly higher compared to previous quarter (+60.6%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 80 | 82 2.5% QoQ | 86 4.9% QoQ | 66 -23.3% QoQ |
| 2020 | 124 55.0% YoY 87.9% QoQ | 86 4.9% YoY -30.6% QoQ | 25 -70.9% YoY -70.9% QoQ | 109 65.2% YoY 336.0% QoQ |
| 2021 | 110 -11.3% YoY 0.9% QoQ | 373 333.7% YoY 239.1% QoQ | 0 -100.0% YoY -100.0% QoQ | 134 22.9% YoY inf% QoQ |
| 2022 | 34 -69.1% YoY -74.6% QoQ | 226 -39.4% YoY 564.7% QoQ | 59 inf% YoY -73.9% QoQ | 125 -6.7% YoY 111.9% QoQ |
| 2023 | 169 397.1% YoY 35.2% QoQ | 0 -100.0% YoY -100.0% QoQ | 196 232.2% YoY inf% QoQ | 94 -24.8% YoY -52.0% QoQ |
| 2024 | 63 -62.7% YoY -33.0% QoQ | - | - | - |
The average 5 years interest of Galectin Therapeutics news was 8.59 per week. The last year interest of Galectin Therapeutics news compared to the last 5 years has changed by -3.26%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 28.64%.
There is not enough data for Galectin Therapeutics stock price to provide analysis
There is not enough data for Galectin Therapeutics stock price to provide correlation calculation
There is not enough data for Galectin Therapeutics stock price to provide analysis
There is not enough data for Galectin Therapeutics clinical trials to provide analysis
There is not enough data for Galectin Therapeutics clinical trials to provide correlation calculation
There is not enough data for Galectin Therapeutics clinical trials to provide analysis
There is not enough data for Galectin Therapeutics liver fibrosis to provide analysis
There is not enough data for Galectin Therapeutics liver fibrosis to provide correlation calculation
There is not enough data for Galectin Therapeutics liver fibrosis to provide analysis
There is not enough data for Galectin Therapeutics belapectin to provide analysis
There is not enough data for Galectin Therapeutics belapectin to provide correlation calculation
There is not enough data for Galectin Therapeutics belapectin to provide analysis
There is not enough data for Galectin Therapeutics fatty liver disease treatment to provide analysis
There is not enough data for Galectin Therapeutics fatty liver disease treatment to provide correlation calculation
There is not enough data for Galectin Therapeutics fatty liver disease treatment to provide analysis
There is not enough data for Galectin Therapeutics cancer therapy to provide analysis
There is not enough data for Galectin Therapeutics cancer therapy to provide correlation calculation
There is not enough data for Galectin Therapeutics cancer therapy to provide analysis
There is not enough data for Galectin Therapeutics research and development to provide analysis
There is not enough data for Galectin Therapeutics research and development to provide correlation calculation
There is not enough data for Galectin Therapeutics research and development to provide analysis